Recombinant antibodies (rAbs) are thriving in the dynamic field of antibody research. Creative Biolabs leads the way in producing cutting-edge rAb solutions that enable advances across diverse scientific domains. Novel Antibodies Shape What Lies Ahead The premise of genetic precision is the building block of recombinant antibodies. Their production bypasses hybridoma instability, ensuring unparalleled lot-to-lot consistency—a critical advantage for long-term and large-scale studies. Moreover, rAbs are inherently scalable, with production systems optimised for high-yield output from host cell lines, such as mammalian or bacterial platforms. Creative Biolabs: A Trustworthy Partner in rAb Development Creative Biolabs has built a reputation for excellence in recombinant antibody development, leveraging the latest advances in DNA recombination technology to produce antibodies that redefine industry standards. Revolutionary DevelopmentThe Hi-Affi™ recombinant antibody platform ensures precision engineering of antibodies tailored for diverse research needs to offer single-domain antibodies, bispecific antibodies, and Fab fragments, giving researchers a wealth of options to match their project goals. High-Throughput ProductionTime is money, and AI-driven antibody production solutions are designed to deliver with speed and accuracy—use a wide variety of AI models for optimising regular antibody development process, as well as employ advanced machine learning algorithms plus extensive datasets to effectively predict the most promising candidates. With robust workflows optimised for stability, customisability, and rapid delivery, they help researchers stay ahead of deadlines while meeting the most stringent quality benchmarks. Non-GMP Production for Flexible Applications For preclinical studies and exploratory research, Creative Biolabs offers non-GMP antibody production that ensures to yield high-quality antibodies without the overhead of GMP manufacturing, making it an efficient option for initial project phases or non-therapeutic applications. Upcoming Exhibition Creative Biolabs will showcase their recombinant antibody expertise at the Scientist Solution Vendor Event – NIH 37 this December and at Antibody Engineering & Therapeutics (US) 2024 later in the month. “These events are the perfect opportunity to connect with our scientists,” a scientist at Creative Biolabs says, “whether you’re looking to scale production, refine an antibody’s specificity, or explore novel applications. Web: https://www.creativebiolabs.net/

Creative Biolabs Hits the Ground Running at the 21st BioPharma Drug Discovery Nexus Conference   Creative Biolabs attended the 21st BioPharma Drug Discovery Nexus Conference as an exhibitor for the first time on October 22–23.   “This event, a major hub for service providers and industry leaders, presented us with an incredible opportunity to showcase our innovative technologies in antibody discovery and to connect with key players in the drug discovery field,” according to one of the delegates, “and at the first day in exhibition hours, our booth became a hotspot for attendees eager to explore our solutions, particularly in areas like monoclonal antibody discovery.”   With a lot of expertise in drug discovery, Creative Biolabs seized the opportunity to highlight their core capabilities, including epitope mapping and immune repertoire analysis, laying the groundwork for potential collaborations and new business prospects.   Leveraging various immunized antibody libraries, Creative Biolabs handles the precise and efficient identification of therapeutic antibodies with high specificity and affinity from various host species, including human, monkey, mouse, rat, rabbit, chicken, and camel, tremendously enhancing the likelihood of discovering antibodies that can effectively target elusive antigens and expediting the drug development process.   “Our scientists are confident in generating antibody libraries with a diversity of 10^8 to 10^10, sufficient to meet the requirements of most research endeavors. Our significant experience contributes to developing optimal biopanning strategies for the selection of reliable antibodies characterized by high specificity and affinity.” The delegate says.   In a move that further demonstrates their dedication to the advancement of therapeutic antibody discovery, Creative Biolabs presented the robust epitope mapping & discovery service, patented as CreMap™, which opens up the way to the exact identification of antibody binding sites and critically provides insights into the functional regions of proteins to enable researchers to fine-tune antibody-antigen interactions for the functional optimization of therapeutic antibodies.   Additionally, they demonstrated mastery of immune repertoire analysis, a foundational skill for analyzing the diversity and specificity of B cell receptors (BCRs) and T cell receptors (TCRs), offering an in-depth understanding of how the immune system responds to pathogens and other foreign “intruders”, establishing merits in both diagnostic and therapeutic scopes.   “Our presence at the 21st BioPharma Drug Discovery Nexus Conference, even for the first time, is not only a stage to showcase these capabilities but also a critical move toward expanding our footprint in the global biopharma market.” The delegate concludes. “We’re determined to capitalize on opportunities for further engagement with industry experts, fostering new partnerships, and expanding its reach within the antibody engineering community at future events.”   Building on the momentum from the conference, Creative Biolabs is gearing up for a busy schedule in the final quarter of 2024. The company is set to exhibit at the Annual World ADC San Diego in November, followed by the Scientist Solution Vendor Event – NIH 37 in December, and the Antibody Engineering & Therapeutics (US) 2024.   For additional information, visit https://www.creative-biolabs.com/.   About With the growing importance of personalized medicine and the constant demand for novel therapeutic antibodies, Creative Biolabs seized the opportunity to engage with pharma and biotech companies, offering tailored solutions to accelerate their drug discovery pipelines.